Schering-Plough Articles
Stock Commentary - New York
28 July 2003
Generics push S-P profits down 71%
28 July 2003
Stock Commentary - New York
16 June 2003
US generics approvals for Teva and B&L
16 June 2003
S-P set to face criminal charges in USA?
9 June 2003
Cost-cutting reaps dividends at Shionogi
2 June 2003
S-P's Remicade cleared in EU for Crohn's, AS
26 May 2003
Fast growth forecast for hep C drug market
19 May 2003
Stock Commentary - New York
19 May 2003
S-P's new CEO sets out turnaround plan
19 May 2003
ICN Pharma 1st-qtr revenues fall 14%
12 May 2003
$1.1 bill buyback at Aventis as profits fall
5 May 2003
US FDA "has authority for Rx-OTC switches"
5 May 2003
Hassan takes biggest pay rise in 2002 CEO compensation
28 April 2003
Stock Commentary - New York
21 April 2003
S-P, Novartis link up on asthma product
21 April 2003
Stock Commentary - New York
14 April 2003
Chugai USA names David Mazzo CEO
14 April 2003
California directs HMOs over switched drugs
7 April 2003
Threats to innovation could see drug R&D fall into a "death spiral," says Eli Lilly CEO
7 April 2003
Stock Commentary - New York
31 March 2003
Teva and Novartis strike deal with S-P
31 March 2003
Connecticut sues seven drugmakers
24 March 2003
Stock Commentary - New York
17 March 2003
ICN Pharma posts 4th-qtr EPS loss of $1.20
17 March 2003
Pharmagene sees 12% hike in 2002 sales
17 March 2003
Schering-Plough gives $0.75-$0.85 EPS guide
17 March 2003
S-P gets patent extension for Clarinex
3 March 2003
Pierr Fabre names Roch Doliveux as deputy DG
3 March 2003
Stock Commentary - New York
3 March 2003
S-P takes $150M charge, restates 2002 earnings
3 March 2003
Remicade backed for new indication in EU
3 March 2003
Stock Commentary - Week to Feb 10 - New York
17 February 2003
Schering-Plough files debt shelf-registration
17 February 2003
2002's crop of new product launches backs up R&D fears
10 February 2003
Sepracor improves position in 2002
10 February 2003
Update: Biogen gets US approval for Amevive
10 February 2003
Leiner to tackle private-label OTC loratadine market
10 February 2003
Impax' generic Claritin cleared in USA
10 February 2003
Biogen's Amevive cleared for psoriasis
10 February 2003
Stock Commentary - Week to January 27 - New York
3 February 2003
Biogen profits rocket in fourth quarter
3 February 2003
Millennium losses beat consensus in 4th qtr
3 February 2003
Schering-Plough KK appoints Hiroshi Mabuchi
3 February 2003
Looming Claritin rivals cut S-P shares 7%
3 February 2003
Claritin switch hits S-P, sales down 4% in 2002
3 February 2003
S-P launches Asmanex Twisthaler for asthma in UK
27 January 2003
Stock Commentary - week to Jan 20 - New York
27 January 2003
S-P's Caelyx gets new indication in EU
20 January 2003
S-P promotes Catherine Strader
20 January 2003
Roche undercuts rival with ribavirin brand
20 January 2003
S-P lowers forecast as Claritin rivalry bites
20 January 2003
Round-up of pharmaceutical mergers and acquisitions during 2001
13 January 2003
Update - Wyeth gets final OTC Claritin approval
6 January 2003
Abbott gets approval for blockbuster candidate Humira in USA
6 January 2003
Wyeth gets final OTC Claritin approval
6 January 2003
Claritin generics "will cut US Rx market 15%"
19 August 2002
S-P to appeal Claritin patent ruling
19 August 2002
Ribapharm sues Roche for patent infringement
12 August 2002
SciQuest posts $3.4 million net loss
5 August 2002
Millennium revenues leap upwards 55%
29 July 2002
Taro Pharma 2nd qtr sales up 336%
29 July 2002
S-P gains infant indication for Nasonex
29 July 2002
Millenium revenues leap 55% in 2nd qtr
29 July 2002
FDA grants Pegasys fast-track review
22 July 2002
S-P pulls out of alliance with Zonagen on ED
22 July 2002
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
